EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Simvastatin competitively inhibits cellular signaling of lipid-binding antiphospholipid antibodies

Dominika Marova, Paul Frankenbach, Anne Hollerbach, Susanne Strand, Wolfram Ruf, Karl J Lackner, Nadine Müller-Calleja

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2025.08.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Dominika Marova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. Hauptthemen laut MEDLINE: Monocytes, Simvastatin, Antibodies, Antiphospholipid, Signal Transduction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, Foundation for Pathobiochemistry and Molecular Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Antiphospholipid antibodies (aPLs) cause antiphospholipid syndrome (APS), a disease characterized by thrombotic events and/or pregnancy morbidity. Some clinical studies suggest that statins may beneficially affect the course of APS. OBJECTIVES: In this study, we studied the effect of statins on aPL-induced monocyte activation, aPL-triggered tissue factor (TF) activation, and the underlying cellular mechanisms. METHODS: Cultured monocytes were treated with human monoclonal lipid-binding aPLs or total immunoglobulin G fractions positive for cardiolipin antibodies with or without statins. Expression of TF and tumor necrosis factor α (TNFα) messenger RNA was measured by real-time quantitative polymerase chain reaction. TF activity was determined using clotting assay. The effects of statins on the binding and internalization of aPL were determined by confocal microscopy and flow cytometry. RESULTS: Simvastatin completely inhibited the induction of TNFα and TF messenger RNA by human lipid-binding aPLs. Simvastatin also prevented TF activation by aPL on the cell surface. These effects were not mediated by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition, but simvastatin and other statins prevented lipid-binding aPLs from binding to their cell-surface target, ie, lysobisphosphatidic acid (LBPA) presented by the endothelial protein C-receptor (EPCR) by displacement of LBPA. Competition experiments indicate that statins displace LBPA from the hydrophobic groove of EPCR. Consequently, aPLs could not induce any downstream cellular effects. CONCLUSION: Our data show that statins prevent monocyte activation and TF-triggered coagulation by interfering with binding of lipid-binding aPLs to the EPCR/LBPA complex on the cell surface of monocytes. These findings may help to understand the observed beneficial effects of statins in APS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MonocytesSimvastatinAntibodies, AntiphospholipidSignal TransductionHydroxymethylglutaryl-CoA Reductase InhibitorsHumansThromboplastinTumor Necrosis Factor-alphaAntiphospholipid SyndromeCells, CulturedRNA, MessengerBlood CoagulationProtein Binding

Stichwörter der Autor:innen

antiphospholipid syndromeendothelial protein C receptorlysobisphosphatidic acidpleiotropic effectssimvastatin

Substanzen

ThromboplastinSimvastatinAntibodies, AntiphospholipidHydroxymethylglutaryl-CoA Reductase InhibitorsTumor Necrosis Factor-alphaRNA, MessengerTNF protein, human

Autor:innen und Institutionen

  • Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
  • Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
  • Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany; Department of Immunology and Microbiology, Scripps Research, La Jolla, California, USA; German Center…
  • Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany; Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gu…

Förderung

  • German Research Foundation
  • Foundation for Pathobiochemistry and Molecular Diagnostics

Zitieren

APA

Marova, D., Frankenbach, P., Hollerbach, A., Strand, S., Ruf, W., Lackner, K. J., & Müller-Calleja, N. (2025). Simvastatin competitively inhibits cellular signaling of lipid-binding antiphospholipid antibodies. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.08.027

Vancouver

Marova D, Frankenbach P, Hollerbach A, Strand S, Ruf W, Lackner KJ, et al. Simvastatin competitively inhibits cellular signaling of lipid-binding antiphospholipid antibodies. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.08.027

BibTeX
@article{Marova2025,
  author = {Marova, Dominika and Frankenbach, Paul and Hollerbach, Anne and Strand, Susanne and Ruf, Wolfram and Lackner, Karl J and Müller-Calleja, Nadine},
  title = {Simvastatin competitively inhibits cellular signaling of lipid-binding antiphospholipid antibodies},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2025.08.027}
}
Kostenlos starten →